Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Sanofi

Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability

Sanofi SA (NASDAQ:SNY) shared new data from the HS-OBTAIN phase 2a study, which shows that treatment with brivekimig led to clinically meaningful improvements in the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR50) in patients naïve to biologics with moderate-to-severe hidradenitis suppurativa (HS).

Benzinga

Britain is ‘a terrible place’ to sell medicines, says drug firm executive

Sanofi’s market access chief urges ministers to come up with a roadmap to raise spending on new treatments

The Guardian - UK

Roblox To Rally Around 34%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

This Veeva Systems Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga

AI might beat IQ, not EQ — but never say never

We underestimate the scale of the AI learning curve, says Paul Hudson, CEO of Sanofi.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts

A federal appeals court has revived a proposed class action accusing four major drugmakers of conspiring to restrict a government-mandated drug discount program, allegedly driving up costs for safety-net hospitals and clinics serving low-income patients.

Benzinga

Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount

With investors concerned about overall economic stability amid the Trump administration's tariff impact, they're not in a particularly generous mood. That may be the lesson learned the hard way by global pharmaceutical giant Sanofi SA (NASDAQ:SNY). Despite delivering an earnings report that offered an encouraging view, it wasn't a perfect…

Benzinga

Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales

Sanofi SA (NASDAQ:SNY) reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.

Benzinga

Why Thermo Fischer Stock Is Rising Wednesday

Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported second-quarter 2025 adjusted earnings of $5.36 per share, beating the street view of $5.23.

Benzinga

Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, U.K.

Benzinga

Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus vaccines and add a non-mRNA vaccine to its pipeline.

Euronews

New therapy teplizumab could delay type 1 diabetes by years – if caught early

For more than a century, type 1 diabetes has meant one thing: a lifetime administering insulin. But for the first time, science is breaking that paradigm – not by managing the disease, but by intercepting it before symptoms even appear.

The Conversation

Get all your
news in one place.

100's of premium titles.
One news app.

Radio France Internationale

French drug giant Sanofi plans massive US investment to counter Trump tariffs

French pharmaceutical giant Sanofi plans to invest billions of euros to expand its manufacturing in the United States, in response to President Donald Trump’s trade policies – which include threats to impose tariffs on medicines in order to increase homegrown production.

Fortune

Chrissy Teigen is sharing what it was like to see her son Miles, 6 diagnosed with Type 1 diabetes: 'It was just so shocking'

“All of a sudden we were just thrown into having to learn everything imaginable the same day that he needed to start shots,” Teigen recounts.

LiveScience

Acne vaccine: Experimental shot for common skin condition reaches clinical trials. Here's what you need to know.

An experimental vaccine for acne could someday transform the way patients with the condition are treated, according to the company that developed the shot. However, it is still early days.

Fortune

Europe’s pharma titans confront von der Leyen as Trump plans ’major’ tariffs

Novo Nordisk and Sanofi were among the companies threatening to hasten their exits to the U.S., as Trump promised pharma tariffs were coming “shortly.”

Get all your
news in one place.

100's of premium titles.
One news app.

inkl

How Diabetes Patients Are Fighting for Affordable Insulin

The World Health Organization states that there were around 830 million people living with diabetes in 2022. More than half of them weren't taking diabetes medications, including insulin, likely due to access and cost issues.

Fortune

Sanofi exec says remote work takes away employee 'serendipity'

"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are becoming the norm.”

MarketBeat

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

StockNews.com

3 Gene Therapy Stocks With Game-Changing Potential

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, investing in gene therapy stocks like Pfizer (PFE), Sanofi (SNY), and Novartis AG (NVS) could be beneficial. Read on….

Fortune

Why Olympian Jordan Chiles is raising awareness of type 1 diabetes

“If I had type 1 diabetes as an athlete, I don't think I could be as strong as how my aunt is right now," Chiles says about her inspiration for advocacy work.

Barchart

3 Pharma Stocks to Buy as California Sounds the Alarm on Bird Flu Cases

The bird flu crisis is creating investment opportunities in the pharmaceutical sector, with Sanofi, GSK, and CSL Limited emerging as top picks.

Fortune

Sanofi exec says remote work takes away employee 'serendipity'

“I think we were contrarians,” Sanofi’s chief digital officer, Emmanuel Frenehard, told Fortune. “I think the contrarians are becoming the norm.”

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.